RESUMO
OBJECTIVE: To assess the economic impact of introducing biosimilars of bevacizumab for the management of cancer patients receiving systemic bevacizumab in the National Health System (SNHS) of Spain. METHODS: A 3-year budget impact analysis model was adapted to estimate the cost of introducing biosimilars of bevacizumab in the SNHS for the adult population who were candidates to receive treatment with bevacizumab. Values for the estimation of the population were obtained from the literature and were validated by an expert panel. In this analysis only pharmaceutical costs (, year 2021) obtained from official databases were considered. A sensitivity analysis was performed to examine the robustness of the model. RESULTS: The introduction of bevacizumab biosimilars would generate an annual cost saving of 11 558 268 (-5.1%) for the first year with a penetration share of biosimilars from 30.0%, 29 126 373 (-8.5%) for the second year with a share of 50.0% and 52 361 778 (-13.6%) for the third year with a share of 80.0%. The total pharmaceutical costs of the scenario without biosimilars are 227 033 352 for the first year, 342 663 209 for the second year and 385 013 076 for the third year. In contrast, the pharmaceutical costs of the scenario with bevacizumab biosimilars are 215 475 084, 313 536 836 and 332 651 297 for years 1, 2 and 3, respectively. CONCLUSIONS: The introduction of biosimilars in the Spanish Health System would generate saving costs in the pharmacological budget to boost biological drugs from the first year.
Assuntos
Medicamentos Biossimilares , Neoplasias , Humanos , Adulto , Bevacizumab/uso terapêutico , Medicamentos Biossimilares/uso terapêutico , Espanha/epidemiologia , Preparações Farmacêuticas , Neoplasias/tratamento farmacológico , Neoplasias/epidemiologiaRESUMO
Objectives: The study aimed to estimate the burden of metastatic breast cancer (mBC) in Spain over 5 years. Methods: An incidence-based cost-of-illness model was developed in which a cohort of patients with mBC was followed from the diagnosis of metastatic disease over 5 years or death. Resource use data were collected through a physician survey conducted with 10 clinical experts in Spain. The model distinguished patients according to HER2 and hormonal receptor (HR) status, and followed the patient cohort in monthly cycles. Results: The incident cohort was estimated to be 2,923 patients with mBC, consisting of 1,575 HER2-/HR+, 520 HER2+/HR+, 324 HER2+/HR-, and 503 triple negative patients. The estimated mean survival over the 5-year time period was 2.51 years, on average, with longer survival of 3.36 years for HER2+/HR+, 2.41 years for HER2-/HR+, 2.82 years for HER2+/HR- and shortest mean survival of 1.74 years for triple negative patients. The total costs were 469,92,731 for the overall population, 190,079,787 for the HER2-/HR+, 151,045,260 for the HER2+/HR+, 80,827,171 for the HER2+/HR- and 47,540,512 for the triple negative subgroups over 5 years. Per patient total costs were 160,642 on average, 120,664 for HER2-/HR+, 290,346 for HER2+/HR+, 249,152 for HER2+/HR-and 94,572 for triple negative patients over 5 years. Conclusions: The economic burden of mBC in Spain is significant, but differs by HER2 and HR status. HER2-/HR +patients account for the highest burden due to the prevalence of this category, but HER2+/HR +patients have the highest per patient costs.
Assuntos
Neoplasias da Mama/economia , Neoplasias da Mama/epidemiologia , Efeitos Psicossociais da Doença , Custos de Cuidados de Saúde/tendências , Protocolos de Quimioterapia Combinada Antineoplásica/economia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/terapia , Estudos de Coortes , Feminino , Seguimentos , Humanos , Metástase Neoplásica , Receptor ErbB-2 , Espanha/epidemiologia , Taxa de Sobrevida/tendências , Neoplasias de Mama Triplo Negativas/economia , Neoplasias de Mama Triplo Negativas/epidemiologia , Neoplasias de Mama Triplo Negativas/terapiaRESUMO
No disponible
Assuntos
Feminino , Humanos , Masculino , /organização & administração , /estatística & dados numéricos , /normas , Sistemas Nacionais de Saúde , Preparações Farmacêuticas/normas , Conhecimento , Gestão do Conhecimento para a Pesquisa em Saúde , Gestão do Conhecimento/estatística & dados numéricosRESUMO
Future costs are not usually included in economic evaluations. The aim of this study was to assess the extent of published economic analyses that incorporate future costs. A systematic review was conducted of economic analyses published from 2008 to 2013 in three general health economics journals: PharmacoEconomics, Value in Health and the European Journal of Health Economics. A total of 192 articles met the inclusion criteria, 94 of them (49.0%) incorporated future related medical costs, 9 (4.2%) also included future unrelated medical costs and none of them included future nonmedical costs. The percentage of articles including future costs increased from 2008 (30.8%) to 2013 (70.8%), and no differences were detected between the three journals. All relevant costs for the perspective considered should be included in economic evaluations, including related or unrelated, direct or indirect future costs. It is also advisable that pharmacoEconomic guidelines are adapted in this sense.
Assuntos
Farmacoeconomia/tendências , Custos de Cuidados de Saúde/tendências , Publicações Periódicas como Assunto/estatística & dados numéricos , Custos e Análise de Custo/métodos , Atenção à Saúde/economia , HumanosAssuntos
Custos de Medicamentos , Gastos em Saúde , Programas Nacionais de Saúde/economia , Atenção Primária à Saúde/economia , Resultado do Tratamento , Controle de Custos , Análise Custo-Benefício , Uso de Medicamentos/economia , Uso de Medicamentos/estatística & dados numéricos , Humanos , EspanhaRESUMO
No disponible
No disponible
Assuntos
Humanos , Drogas em Investigação , Avaliação de Medicamentos/métodos , Medicamentos de Referência , Indústria Farmacêutica/tendênciasRESUMO
No disponible
Assuntos
Humanos , Controle de Medicamentos e Entorpecentes , Legislação de Medicamentos , Política de Saúde , Política Pública , EspanhaRESUMO
No disponible
Assuntos
Humanos , Aplicação de Novas Drogas em Teste/economia , Análise Custo-EficiênciaRESUMO
No disponible
No disponible
